Stephane Champiat, Luke Kuttschreuter, Neal Shiv Chawla, Louise Carter, Steven Chuan-Hao Kao, Victoria K. Woodcock, Sarah Benafif, T.R. Jeffry Evans, Timothy Guy Humphries, Harriet S. Walter, Andy Karabajakian, Alexandre Grimaldi, Caroline Hoffmann, Andrew Pierce, Kamlesh Kumar Sankhala. "Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps2681